The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

(HealthDay News) — Preventive psychological interventions may be effective for adults with subthreshold depressive symptoms, according to a review published online in the December issue of The Lancet ...

Biochemical analyses provide an answer to the question of how the gut bacterium Morganella morganii might contribute to some ...

A non-invasive form of treatment for clinical depression is hoping to provide even faster results thanks to new research.

Neurocrine Biosciences amended its agreement with Takeda Pharmaceutical regarding the development and commercialization of osavampator, a treatment for major depressive disorder.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...